Myocardial infarction is a major cause of morbidity and mortality in the United States and most developed countries. Heart transplantation is an effective therapeutic modality in reconstituting the function of damaged heart. However, widespread application of this modality is severely limited due to the scarcity of organ donors and complications associated with the required immunosuppression. Cell therapies aiming at replacing infracted heart muscle are highly desirable. Recent advances in the generation of patient-specific human induced pluripotent stem cells (hiPSCs) have sparked hopes that these cells can serve as an inexhaustible source of cellular material for repairing damaged myocardium. Like human embryonic stem cells (hESCs), hiPSCs have been shown to differentiate towards functional cardiomyocytes utilizing embryoid body (EB) culture and serum-supplemented media. Nonetheless, clinical realization of stem cell-based therapies for heart repair will require the production of hiPSC-derived cardiomyocytes (i) using directed differentiation methods free of animal components (e.g. serum), and (ii) in large numbers. We hypothesize that hiPSCs can be directed towards cardiomyocyte-like cells with physiologically relevant factors known to participate in embryonic heart development. To that end, we propose to establish a method for the directed differentiation of hiPSCs to stem cardiac cells in static cultures (e.g. dishes). However, the propagation and differentiation of iPSCs in dishes are challenging to scale-up. We have discovered that hESCs cultivated in a bioreactor can be expanded several fold and differentiate to multiple lineages. Then, our second hypothesis is that hiPSCs cultured on microcarriers in stirred-suspension bioreactors can also be propagated to high concentrations. We propose to culture hiPSCs in a stirred bioreactor culture system and determine conditions which favor the growth of hiPSCs without compromising their pluripotency and viability. Furthermore, stem cell differentiation to cardiac cells is typically carried out in EB cultures. Given that not all cells within EBs are exposed to cardiogenic factors, this process is challenging to control and is characterized by poor efficiency. Therefore, expansion of hiPSCs on microcarriers may be followed by switching to conditions directing the cells to adopt a cardiomyocyte fate. We will evaluate the cardiogenic potential of hiPSCs cultured in microcarrier bioreactors. The resulting cells will be characterized for the expression of cardiomyocyte-associated genes/proteins and will be subjected to functional assays in vitro. Lastly, a mouse infarct heart model will be employed to evaluate the functional attributes of hiPSC-derived heart cells in vivo. This study will yield new information benefiting the development of bioprocesses for the generation of large quantities of hiPSC-derived cardiomyocytes suitable for heart therapies.

Public Health Relevance

Myocardial infarction-induced heart failure is a prevailing cause of death in the United States and clinical therapies aiming at replacing or restoring damaged heart muscle are lacking. Patient-specific human induced pluripotent stem cells, which proliferate extensively and can differentiate towards functional cardiomyocytes, may serve as a renewable cellular source for regenerative heart therapies. This project seeks to further our understanding of the cardiogenic potential of human induced pluripotent stem cells in static and scalable culture systems and to advance bioprocess technologies for the production of stem cell-derived cardiomyocytes in clinically relevant quantities.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Bioengineering, Technology and Surgical Sciences Study Section (BTSS)
Program Officer
Adhikari, Bishow B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
State University of New York at Buffalo
Engineering (All Types)
Schools of Engineering
United States
Zip Code
Fan, Yongjia; Zhang, Fan; Tzanakakis, Emmanuel S (2017) Engineering Xeno-Free Microcarriers with Recombinant Vitronectin, Albumin and UV Irradiation for Human Pluripotent Stem Cell Bioprocessing. ACS Biomater Sci Eng 3:1510-1518
Ashok, Preeti; Fan, Yongjia; Rostami, Mahboubeh R et al. (2016) Aggregate and Microcarrier Cultures of Human Pluripotent Stem Cells in Stirred-Suspension Systems. Methods Mol Biol 1502:35-52
Terranova, Christopher; Narla, Sridhar T; Lee, Yu-Wei et al. (2015) Global Developmental Gene Programing Involves a Nuclear Form of Fibroblast Growth Factor Receptor-1 (FGFR1). PLoS One 10:e0123380
Parikh, Abhirath; Wu, Jincheng; Blanton, Robert M et al. (2015) Signaling Pathways and Gene Regulatory Networks in Cardiomyocyte Differentiation. Tissue Eng Part B Rev 21:377-92
Rostami, Mahboubeh Rahmati; Wu, Jincheng; Tzanakakis, Emmanuel S (2015) Inverse problem analysis of pluripotent stem cell aggregation dynamics in stirred-suspension cultures. J Biotechnol 208:70-9
Wu, Jincheng; Fan, Yongjia; Tzanakakis, Emmanuel S (2015) Increased culture density is linked to decelerated proliferation, prolonged G1 phase, and enhanced propensity for differentiation of self-renewing human pluripotent stem cells. Stem Cells Dev 24:892-903
Fan, Yongjia; Wu, Jincheng; Ashok, Preeti et al. (2015) Production of human pluripotent stem cell therapeutics under defined xeno-free conditions: progress and challenges. Stem Cell Rev 11:96-109
Fan, Yongjia; Hsiung, Michael; Cheng, Chong et al. (2014) Facile engineering of xeno-free microcarriers for the scalable cultivation of human pluripotent stem cells in stirred suspension. Tissue Eng Part A 20:588-99
Wu, Jincheng; Rostami, Mahboubeh Rahmati; Cadavid Olaya, Diana P et al. (2014) Oxygen transport and stem cell aggregation in stirred-suspension bioreactor cultures. PLoS One 9:e102486
Chen, Chih-Kuang; Law, Wing-Cheung; Aalinkeel, Ravikumar et al. (2014) Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells. Nanoscale 6:1567-72

Showing the most recent 10 out of 19 publications